Production (Stage)
Qualigen Therapeutics, Inc.
QLGN
$3.42
-$0.10-2.84%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -855.80K | -1.79M | -1.58M | -2.03M | -2.45M |
| Total Depreciation and Amortization | -- | -- | -- | -- | 4.50K |
| Total Amortization of Deferred Charges | 101.50K | 191.30K | 219.10K | 103.70K | 222.40K |
| Total Other Non-Cash Items | -554.20K | 503.70K | -392.40K | 542.70K | -3.80M |
| Change in Net Operating Assets | -961.00K | -700.80K | 275.30K | 602.80K | 356.10K |
| Cash from Operations | -2.27M | -1.80M | -1.47M | -783.60K | -5.67M |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -1.01M | -1.25M | 350.00K | -- | 235.40K |
| Cash from Investing | -1.01M | -1.25M | 350.00K | -- | 235.40K |
| Total Debt Issued | 0.00 | 2.00M | 1.00M | 475.00K | -- |
| Total Debt Repaid | -499.00K | -2.00M | -- | -- | -110.00K |
| Issuance of Common Stock | 0.00 | 3.32M | 150.00K | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | 4.56M | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 4.06M | 3.32M | 1.15M | 475.00K | -110.00K |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 786.50K | 269.50K | 25.50K | -308.60K | -5.55M |